caa a22 4500 445807857 CHVBK 20180317145202.0 cr unu---uuuuu 170323e20110901xx s 000 0 eng 10.1007/s00415-011-5990-4 doi (NATIONALLICENCE)springer-10.1007/s00415-011-5990-4 Ifosfamide associated myoclonus-encephalopathy syndrome [Elektronische Daten] [Rodolfo Savica, Alejandro Rabinstein, Keith Josephs] The aim of this study was to investigate the presence of movement disorders associated with ifosfamide toxicity. One of the most common adverse events of ifosfamide treatment is central nervous system toxicity. However, little is known about the occurrence of movement disorders associated with ifosfamide toxicity. We performed a retrospective computer search of the electronic medical records database of the Mayo Clinic, Rochester, MN from 1 January 1997-30 June 2010, using a series of search terms to identify all patients that had been treated with ifosfamide for systemic cancer. Among 400 patients that have ever used ifosfamide, we selected those patients that had any neurological complication in their medical records after the use of ifosfamide. Fifty-two had a neurological complication after ifosfamide administration. The most common neurological complication was encephalopathy that was present in 11 cases (21%). The presence of a movement disorder time locked to the administration of ifosfamide was reported in seven cases (13%). Generalized myoclonus was most common, occurring in four patients while postural tremor was documented in the other three. All patients with myoclonus had asterixis. Four of the patients also had encephalopathy. In six patients the movement disorders resolved within 48 h, spontaneously, after the discontinuation of ifosfamide, while in one case resolved in 24h after the treatment with methylene blue. Our study demonstrates that although encephalopathy is the most common adverse neurological event associated with ifosfamide toxicity, movement disorders, including generalized myoclonus, asterixis, and postural tremors may also occur. Treatment with methylene blue may be further considered as useful to ameliorate the movement disorders. Springer-Verlag, 2011 Myoclonus nationallicence Tremor nationallicence Methylene blue nationallicence Encephalopathy nationallicence Ifosfamide nationallicence Savica Rodolfo Department of Neurology, Division of Movement Disorders, Mayo Clinic, 200 1st Street S.W., 55905, Rochester, MN, USA aut Rabinstein Alejandro Department of Neurology, Division of Critical Care Neurology, Mayo Clinic, 55905, Rochester, MN, USA aut Josephs Keith Department of Neurology, Division of Movement Disorders, Mayo Clinic, 200 1st Street S.W., 55905, Rochester, MN, USA aut Journal of Neurology Springer-Verlag 258/9(2011-09-01), 1729-1731 0340-5354 258:9<1729 2011 258 415 https://doi.org/10.1007/s00415-011-5990-4 text/html Onlinezugriff via DOI 1 brief-communication jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s00415-011-5990-4 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Savica Rodolfo Department of Neurology, Division of Movement Disorders, Mayo Clinic, 200 1st Street S.W., 55905, Rochester, MN, USA aut NATIONALLICENCE 700 1- Rabinstein Alejandro Department of Neurology, Division of Critical Care Neurology, Mayo Clinic, 55905, Rochester, MN, USA aut NATIONALLICENCE 700 1- Josephs Keith Department of Neurology, Division of Movement Disorders, Mayo Clinic, 200 1st Street S.W., 55905, Rochester, MN, USA aut NATIONALLICENCE 773 0- Journal of Neurology Springer-Verlag 258/9(2011-09-01), 1729-1731 0340-5354 258:9<1729 2011 258 415 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer